Published: Wed, September 13, 2017
Sci-tech | By Javier West

Analyst Buzz: Teva Pharmaceutical Industries Limited (TEVA)

Analyst Buzz: Teva Pharmaceutical Industries Limited (TEVA)

The stock has "Sell" rating by Compass Point on Wednesday, June 15. However, the company's most recent quarter increase of 42.5% looks attractive.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)'s stock on Monday traded at beginning with a price of $17.88 and when day-trade ended the stock finally gained 19.35% to reach at $18.50. Barclays Capital maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Tuesday, January 31. Analysts at BTIG Research have upgraded the stock rating to a respectable Buy. The company has an average rating of "Hold" and an average price target of $32.65.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.50 on Wednesday.

The Israel-based drugmaker on Monday after the market close announced it had signed a deal to sell its Paragard intrauterine copper contraceptive to Cooper Cos. Inc.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. Focused Wealth Mngmt Incorporated invested in 0.01% or 1,673 shares. The company had revenue of $5.69 billion during the quarter, compared to analysts' expectations of $5.72 billion. The company's past year sales total was 5.56 Million. Analyst Jami Rubin writes, "Investors should feel confident in the company's ability to get more than $2 billion from the sale of assets, which will support the repayment of $5 billion this year". Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

08/24/2017 - Teva Pharmaceutical Industries Limited was downgraded to "underperform" by analysts at Credit Suisse. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & worldwide trademark & copyright laws. They now have a United States dollars 13 price target on the stock. The value of the investment in TEVA decreased from $60,474,000 to $29,157,000 a change of 51.8% for the reporting period. This dividend amount will represent a yeild of $7.14.

Teva, which employs more than 2,000 in Pennsylvania, recently lowered its outlook for the rest of 2017, and cut its dividend payout. This presents short term, intermediate and long term technical levels of Teva Pharmaceutical Industries Limited (TEVA) stock. While the stock price moved along with the volume change, shares are touching $0.92. The firm has "Overweight" rating given on Monday, August 3 by JP Morgan.

"With extensive global pharmaceutical experience, a strong track record executing corporate turnaround strategies, driving growth and worldwide expansion at low incremental cost and delivering on promises to shareholders, as well as a commitment to a culture of compliance, Kåre is the right leader to take Teva to the next level", said Dr. Sol J. Barer, Chairman of Teva's Board of Directors. "Kåre has deep insight into the global pharmaceutical industry and a keen knowledge of the generic and specialty drug markets".

Company chares are trading at $19.28 slightly below $20.66, the stock's 50 day moving average and well below the 200 day moving average of $29.02. Active Investors have to observe some key indicators about shares of Teva Pharmaceutical Industries Limited (TEVA). Sterling Investment Advisors Ltd. now owns 3,900 shares of the company's stock worth $125,000 after buying an additional 100 shares during the last quarter. Teva's board had set out to find a candidate with prior experience at the helm of a drug maker as its fourth CEO in less than six years as the company's woes mounted.

Like this: